Zobrazeno 1 - 10
of 896
pro vyhledávání: '"Johan, Neyts"'
Autor:
Yuxia Lin, Mona Khan, Birgit Weynand, Manon Laporte, Frank Coenjaerts, Darius Babusis, John P. Bilello, Peter Mombaerts, Dirk Jochmans, Johan Neyts
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-12 (2024)
Abstract Human parainfluenza virus type 3 (HPIV-3) can cause severe respiratory tract infections. There are no convenient small-animal infection models. Here, we show viral replication in the upper and lower airways of AG129 mice (double IFNα/β and
Externí odkaz:
https://doaj.org/article/3b9f33250d7041cd861db0e822ff8a0c
Autor:
Dominik Kiemel, Ann-Sophie Helene Kroell, Solène Denolly, Uta Haselmann, Jean-François Bonfanti, Jose Ignacio Andres, Brahma Ghosh, Peggy Geluykens, Suzanne J. F. Kaptein, Lucas Wilken, Pietro Scaturro, Johan Neyts, Marnix Van Loock, Olivia Goethals, Ralf Bartenschlager
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-20 (2024)
Abstract Dengue fever represents a significant medical and socio-economic burden in (sub)tropical regions, yet antivirals for treatment or prophylaxis are lacking. JNJ-A07 was described as highly active against the different genotypes within each ser
Externí odkaz:
https://doaj.org/article/e78ff1b130a7428d836ca61a6614a777
Autor:
Li-Hsin Li, Winston Chiu, Yun-An Huang, Madina Rasulova, Thomas Vercruysse, Hendrik Jan Thibaut, Sebastiaan ter Horst, Joana Rocha-Pereira, Greet Vanhoof, Doortje Borrenberghs, Olivia Goethals, Suzanne J. F. Kaptein, Pieter Leyssen, Johan Neyts, Kai Dallmeier
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-15 (2024)
Abstract To curb viral epidemics and pandemics, antiviral drugs are needed with activity against entire genera or families of viruses. Here, we develop a cell-based multiplex antiviral assay for high-throughput screening against multiple viruses at o
Externí odkaz:
https://doaj.org/article/883693f5cd604c2dad6b91f11a0839d3
Autor:
Letian Song, Shenghua Gao, Bing Ye, Mianling Yang, Yusen Cheng, Dongwei Kang, Fan Yi, Jin-Peng Sun, Luis Menéndez-Arias, Johan Neyts, Xinyong Liu, Peng Zhan
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 14, Iss 1, Pp 87-109 (2024)
The main protease (Mpro) of SARS-CoV-2 is an attractive target in anti-COVID-19 therapy for its high conservation and major role in the virus life cycle. The covalent Mpro inhibitor nirmatrelvir (in combination with ritonavir, a pharmacokinetic enhan
Externí odkaz:
https://doaj.org/article/3f51f2f2ddc7422491491f1bb580fa8a
Autor:
Irene Wanjiru Kiarie, Gyula Hoffka, Manon Laporte, Pieter Leyssen, Johan Neyts, József Tőzsér, Mohamed Mahdi
Publikováno v:
Viruses, Vol 16, Iss 10, p 1607 (2024)
Retroviruses perpetuate their survival by incorporating a copy of their genome into the host cell, a critical step catalyzed by the virally encoded integrase. The viral capsid plays an important role during the viral life cycle, including nuclear imp
Externí odkaz:
https://doaj.org/article/57bb4a1180f94884a606280b15fe17ae
Autor:
Simon Cauchemez, Giulio Cossu, Nathalie Delzenne, Eran Elinav, Didier Fassin, Alain Fischer, Thomas Hartung, Dipak Kalra, Mihai Netea, Johan Neyts, Rino Rappuoli, Mariagrazia Pizza, Melanie Saville, Pamela Tenaerts, Gerry Wright, Philippe Sansonetti, Michel Goldman
Publikováno v:
Frontiers in Science, Vol 2 (2024)
The COVID-19 pandemic accelerated research and innovation across numerous fields of medicine. It emphasized how disease concepts must reflect dynamic and heterogeneous interrelationships between physical characteristics, genetics, co-morbidities, env
Externí odkaz:
https://doaj.org/article/da0e62dbfbd7426c89e6529b3f274d4f
Autor:
Viktor Lemmens, Lara Kelchtermans, Sarah Debaveye, Winston Chiu, Thomas Vercruysse, Ji Ma, Hendrik Jan Thibaut, Johan Neyts, Lorena Sanchez-Felipe, Kai Dallmeier
Publikováno v:
npj Vaccines, Vol 8, Iss 1, Pp 1-12 (2023)
Abstract Ebola virus (EBOV) and related filoviruses such as Sudan virus (SUDV) threaten global public health. Effective filovirus vaccines are available only for EBOV, yet restricted to emergency use considering a high reactogenicity and demanding lo
Externí odkaz:
https://doaj.org/article/6df8991fb9124a22ae07f96ee394ac98
Autor:
Delphine Diana Acar, Wojciech Witkowski, Magdalena Wejda, Ruifang Wei, Tim Desmet, Bert Schepens, Sieglinde De Cae, Koen Sedeyn, Hannah Eeckhaut, Daria Fijalkowska, Kenny Roose, Sandrine Vanmarcke, Anne Poupon, Dirk Jochmans, Xin Zhang, Rana Abdelnabi, Caroline S. Foo, Birgit Weynand, Dirk Reiter, Nico Callewaert, Han Remaut, Johan Neyts, Xavier Saelens, Sarah Gerlo, Linos Vandekerckhove
Publikováno v:
EBioMedicine, Vol 100, Iss , Pp 104960- (2024)
Summary: Background: SARS-CoV-2-neutralizing antibodies (nABs) showed great promise in the early phases of the COVID-19 pandemic. The emergence of resistant strains, however, quickly rendered the majority of clinically approved nABs ineffective. This
Externí odkaz:
https://doaj.org/article/d61b439c0eca42cfae0b6e3405d320a1
Autor:
Rana Abdelnabi, Dirk Jochmans, Kim Donckers, Bettina Trüeb, Nadine Ebert, Birgit Weynand, Volker Thiel, Johan Neyts
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-7 (2023)
Abstract The SARS-CoV-2 main protease (3CLpro) is one of the promising therapeutic targets for the treatment of COVID-19. Nirmatrelvir is the first 3CLpro inhibitor authorized for treatment of COVID-19 patients at high risk of hospitalization. We rec
Externí odkaz:
https://doaj.org/article/5b37fc19f66e4452a1148cda697b09dd
Autor:
Sirle Saul, Marwah Karim, Luca Ghita, Pei-Tzu Huang, Winston Chiu, Verónica Durán, Chieh-Wen Lo, Sathish Kumar, Nishank Bhalla, Pieter Leyssen, Farhang Alem, Niloufar A. Boghdeh, Do H.N. Tran, Courtney A. Cohen, Jacquelyn A. Brown, Kathleen E. Huie, Courtney Tindle, Mamdouh Sibai, Chengjin Ye, Ahmed Magdy Khalil, Kevin Chiem, Luis Martinez-Sobrido, John M. Dye, Benjamin A. Pinsky, Pradipta Ghosh, Soumita Das, David E. Solow-Cordero, Jing Jin, John P. Wikswo, Dirk Jochmans, Johan Neyts, Steven De Jonghe, Aarthi Narayanan, Shirit Einav
Publikováno v:
The Journal of Clinical Investigation, Vol 133, Iss 19 (2023)
Targeting host factors exploited by multiple viruses could offer broad-spectrum solutions for pandemic preparedness. Seventeen candidates targeting diverse functions emerged in a screen of 4,413 compounds for SARS-CoV-2 inhibitors. We demonstrated th
Externí odkaz:
https://doaj.org/article/9cc9d935abdc4025aa6c81ab75a6d932